Supplement to CDC-RFA-CE16-1608: Enhanced State Surveillance of Opioid-Involved Morbidity and Mortality

0
625

Opportunity ID: 294375
Opportunity Number: CDC-RFA-CE16-16080201SUPP17
Opportunity Title: Supplement to CDC-RFA-CE16-1608: Enhanced State Surveillance of Opioid-Involved Morbidity and Mortality
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.136
Eligible Applicants: State governments
Additional Information on Eligibility: State health departments currently funded for the CDC-RFA-CE16-1608– Enhanced State Surveillance of Opioid-Involved Morbidity and Mortality are eligble to apply.
Agency Code: HHS-CDC-NCIPC
Agency Name: Department of Health and Human Services
Centers for Disease Control – NCIPC
Posted Date: Jun 05, 2017
Last Updated Date: Jun 05, 2017
Estimated Synopsis Post Date: Jun 23, 2017
Fiscal Year: 2017
Award Ceiling: $400,000
Award Floor: $90,000
Estimated Total Program Funding: $9,800,000
Expected Number of Awards: 33
Description: The purpose of this supplement is to provide additional funding to support activities that are within the scope of the Enhanced State Surveillance of Opioid-Involved Morbidity and Mortality funding opportunity announcement (CDC-RFA-CE16-1608), hereafter referred to as ESOOS. Because state, county, and city medical examiner and coroners provide critical information on drug overdose deaths collected by ESOOS, a majority of the additional funding will be used to support medical examiners and coroners (ME/Cs) to conduct timely and comprehensive toxicology testing of suspected drug overdose deaths. A portion of the additional funds can be used to support one or more the following activities: 1) link Prescription Drug Monitoring Program (PDMP) information to opioid-related drug overdose deaths, 2) complete abstraction and entry of information from death certificate and ME/C reports on opioid-related fatalities into the State Unintentional Drug Overdose Reporting System (SUDORS) within 3 to 6 months, 3) improve scope and/or data quality collected on emergency department (ED) drug overdose visits, 4) improve timeliness and reporting of emergency medical services (EMS) data, and/or 5) propose innovative projects that fall within the scope of the ESOOS cooperative agreement and are approved by CDC. The targeted outcomes will vary based on the additional activities that are implemented. These funds may be used for the following specific activities that align with the scope of the ESOOS FOA: (1) At least 60% of funds must be given directly to ME/Cs to support and conduct timely and comprehensive toxicology testing, including testing for emerging synthetic opioids, of suspected drug overdose deaths. Guidance on investigation of suspected opioid-related overdose deaths including appropriate toxicology testing has been provided by the National Association of Medical Examiners (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951636/) and a SAMHSA consensus panel (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805449/). Comprehensive drug testing would likely include over-the-counter drugs, prescriptions, and illicit substances. Because illicit opioid substances are being rapidly developed, especially fentanyl analogues, and no national standard toxicology panel exists, the most appropriate panels need to be determined on an ongoing basis by ME/Cs. Panels may include the following: 4-ANPP; 4-Methoxybutyryl Fentanyl; 4-Methylphenethyl Acetyl Fentanyl; AH-7921; Acryl Fentanyl; Beta-hydroxythiofentanyl; Butyryl Fentanyl/Isobutyryl Fentanyl; Carfentanil; Furanyl Fentanyl; MT-45; U-47700; U-50488; Valeryl Fentanyl; alpha-Methyl Fentanyl; ortho-Fluorofentanyl; para-Fluorobutyryl Fentanyl/FIBF; and/or para-Fluorofentanyl. Information on emerging synthetic opioids are released on a quarterly basis by the Special Testing and Research Laboratory’s Emerging Trends Program in the Drug Enforcement Administration. The reports can be accessed at the following link: https://ndews.umd.edu/resources/dea-emerging-threat-reports If ME/C agencies collaborating with ESOOS programs have sufficient resources to conduct timely and comprehensive toxicology testing of suspected drug overdose deaths, ESOOS programs may propose other ways that ME/C agencies can use the funding to enhance the timeliness and quality of ME/C investigations of suspected drug overdose deaths. Funding must be distributed to ME/C agencies, and concept proposals should be submitted to CDC for prior approval. Up to 40% of funds may be used for one or more of the following activities: Linking data from prescription drug monitoring programs (PDMP) to opioid-related overdose deaths and sharing these data with key stakeholders such as ME/Cs. Improving the timeliness of reporting toxicology data in SUDORS for fatal overdoses. Currently, these data are reported within 6 to 8 months of the death, but funds may be used to improve the reporting timeliness to within 3 to 6 months of the death. Improving the scope (e.g., capturing data from more emergency departments in the state) and data quality of ED data (e.g., improving the percentage of hospitals submitting ICD-10, chief complaint, and triage note fields). Improving the timeliness and reporting of EMS data. States would collaborate with CDC to begin sharing case-level EMS data and exploring automatic data uploads through available data platforms. Other innovative projects to improve data quality, data linkages, data timeliness, and/or data reporting that are within the scope of the ESOOS FOA. Concept proposals should be submitted to CDC for prior approval.
Version: Forecast 1





Source link